Development of a Commercial Manufacturing Process for Sotorasib, a First-in-Class KRASG12C Inhibitor

被引：18

作者：

Zhang, Liang ^{[1
]}

Griffin, Daniel J. ^{[1
]}

Beaver, Matthew G. ^{[1
]}

Blue, Laura E. ^{[1
,2
]}

Borths, Christopher J. ^{[1
]}

Brown, Derek B. ^{[1
]}

Caille, Seb ^{[2
]}

Chen, Ying ^{[2
]}

Cherney, Alan H.

Cochran, Brian M. ^{[2
]}

Colyer, John T. ^{[2
]}

Corbett, Michael T. ^{[2
]}

Correll, Tiffany L. ^{[1
]}

Crockett, Richard D. ^{[2
]}

Dai, Xi-Jie ^{[1
]}

Dornan, Peter K. ^{[1
]}

Farrell, Robert P. ^{[2
]}

Hedley, Simon J. ^{[2
]}

Hsieh, Hsiao-Wu ^{[1
]}

Huang, Liang ^{[2
]}

Huggins, Seth ^{[2
]}

Liu, Min ^{[2
]}

Lovette, Michael A. ^{[2
]}

Quasdorf, Kyle ^{[2
]}

Powazinik, William

Reifman, Jonathan ^{[2
]}

Robinson, Jo Anna ^{[2
]}

Sangodkar, Rahul P. ^{[1
]}

Sharma, Sonika ^{[1
]}

Kumar, Srividya Sharvan ^{[1
]}

Smith, Austin G. ^{[2
]}

St-Pierre, Gabrielle ^{[2
]}

Tedrow, Jason S. ^{[2
]}

Thiel, Oliver R. ^{[1
]}

Truong, Jonathan V. ^{[1
]}

Walker, Shawn D. ^{[1
]}

Wei, Carolyn S.

Wilsily, Ashraf

Xie, Yong ^{[1
]}

Yang, Ning ^{[1
]}

Parsons, Andrew T. ^{[1
]}

机构：

[1] Amgen Inc, Pivotal & Commercial Synthet, Cambridge, MA 02142 USA

[2] Amgen Inc, Prepivotal Attribute Sci, Thousand Oaks, CA 91320 USA

来源：

ORGANIC PROCESS RESEARCH & DEVELOPMENT | 2022年 / 26卷 / 11期

关键词：

atropisomerism; axial chirality; acrylamide; KRAS; Suzuki-Miyaura; POCl3; chlorination; BOC; palladium; cross-coupling; covalent inhibitor; catalysis; AMG; 510;

D O I：

10.1021/acs.oprd.2c00249

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

A commercial process to manufacture sotorasib (AMG 510), a first-in-class KRASG12C inhibitor, is described. Development efforts focused on rendering a fit-for-purpose early-phase route into a viable long-term commercial process through the reduction of side reactions to improve yield and product quality, as well as reducing cycle times of crystallization processes by improving particle properties and filtration times. These improvements were key to ensuring clinical supply and commercial launch. The final route consists of five synthetic operations from starting material M-1, including a telescoped two-step sequence, and a final form

引用

页码：3115 / 3125

页数：11

共 50 条

[1] Sotorasib in KRASG12C mutated lung cancer
Olivier, Timothee
Prasad, Vinay
LANCET, 2024, 403 (10422):
[2] Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer
Ganguly, Arghya
Yoo, Euna
TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (06) : 536 - 537
[3] Sotorasib/SHP2 inhibitors combo, KRASG12C(ON)I and RASMULTI(ON)I effectively target KRASG12C tumors developing secondary resistance to Sotorasib via KRASG12C amplification
Solanki, Hitendra S.
Imbody, Denis
Desai, Bina
Kato, Ryoji
Stewart, Paul A.
Stern, Yaakov
Majumder, Anurima
Bridenstine, Liznair
Sarca, Bhaswati
Miroshnychenko, Dada
Aronchik, Ida
Marusyk, Andriy
Haura, Eric B.
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[4] Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment
Janne, Pasi A.
Bigot, Frederic
Papadopoulos, Kyriakos
Eberst, Lauriane
Sommerhalder, David
Lebellec, Loic
Voon, Pei Jye
Pellini, Bruna
Kalinka, Ewa
Arbour, Kathryn
Herzberg, Benjamin
Boni, Valentina
Bordenave, Stephanie
Lee, Hyun Woo
Ou, Sai I.
Riess, Jonathan Wesley
Beck, Joseph T.
Ponz-Sarvise, Mariano
Ascierto, Paolo Antonio
Choi, Yoon Ji
Yang, Michelle
Bao, Lei
Raman, Rakesh
Yang, Luxi
Mu, Yunming
Wong, Sofia
Dua, Richa
Johnson, Melissa
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[5] KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, David S.
Fakih, Marwan G.
Strickler, John H.
Desai, Jayesh
Durm, Gregory A.
Shapiro, Geoffrey I.
Falchook, Gerald S.
Price, Timothy J.
Sacher, Adrian
Denlinger, Crystal S.
Bang, Yung-Jue
Dy, Grace K.
Krauss, John C.
Kuboki, Yasutoshi
Kuo, James C.
Coveler, Andrew L.
Park, Keunchil
Kim, Tae Won
Barlesi, Fabrice
Munster, Pamela N.
Ramalingam, Suresh S.
Burns, Timothy F.
Meric-Bernstam, Funda
Henary, Haby
Ngang, Jude
Ngarmchamnanrith, Gataree
Kim, June
Houk, Brett E.
Canon, Jude
Lipford, J. Russell
Friberg, Gregory
Lito, Piro
Govindan, Ramaswamy
Li, Bob T.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (13): : 1207 - 1217
[6] BBO-8520, a first-in-class, direct inhibitor of KRASG12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding
Maciag, Anna E.
Stice, James
Wang, Bin
Sharma, Alok
Chan, Albert
Lin, Ken
Singh, Devansh
Dyba, Marcin
Yang, Yue
Setoodeh, Saman
Smith, Brian P.
Rabara, Dana
Zhang, Zuhui
Larsen, Erik K.
Esposito, Dom
Denson, John Paul
Ranieri, Michela
Meynardie, Mary
Mehdizadeh, Sadaf
Alexander, Patrick
Blanco, Maria Abreu
Turner, David
Xu, Rui
Lightstone, Felice C.
Wong, Kwok Kin
Simanshu, Dhirendra
Wang, Keshi
Stephen, Andrew G.
Sinkevicius, Kerstin
Nissley, Dwight V.
Wallace, Eli
McCormick, Frank
Beltran, Pedro J.
CANCER RESEARCH, 2024, 84 (07)
[7] Sotorasib shows clinical benefits in KRASG12C colorectal cancer
Di Lellis, Maddalena Angela
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (05):
[8] Sotorasib in KRASG12C mutated lung cancer - Authors' reply
Paz-Ares, Luis
Mehta, Bhakti
Wang, Yang
Obiozor, Cynthia
Waterhouse, David
de Langen, Adrianus Johannes
LANCET, 2024, 403 (10422): : 145 - 146
[9] KRASG12C inhibitor: combing for combination
Chakraborty, Atanu
BIOCHEMICAL SOCIETY TRANSACTIONS, 2020, 48 (06) : 2691 - 2701
[10] DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with the KRASG12C inhibitor sotorasib resulting in tumor regression in KRAS mutant NSCLC xenograft models
McMahon, Martin
Bogdan, Madhumita
Timson, Mary J.
Al-Hashimi, Hikmat
Ghazi, Phaedra
Zhan, Yu
Smith, Bryan D.
Kinsey, Conan G.
Flynn, Daniel L.
CANCER RESEARCH, 2022, 82 (12)

← 1 2 3 4 5 →